6FY0 image
Deposition Date 2018-03-10
Release Date 2018-11-21
Last Version Date 2024-11-13
Entry Detail
PDB ID:
6FY0
Keywords:
Title:
Crystal structure of a V2-directed, RV144 vaccine-like antibody from HIV-1 infection, CAP228-16H, bound to a heterologous V2 peptide
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.57 Å
R-Value Free:
0.25
R-Value Work:
0.21
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:CAP45 V2 peptide
Chain IDs:E (auth: A), F (auth: P)
Chain Length:19
Number of Molecules:2
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:CAP228-16H Heavy Chain
Chain IDs:A (auth: H), D (auth: I)
Chain Length:235
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:CAP228-16H Light Chain
Chain IDs:B (auth: L), C (auth: M)
Chain Length:213
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity.
Cell Rep 25 3123 3135.e6 (2018)
PMID: 30540944 DOI: 10.1016/j.celrep.2018.11.058

Abstact

Antibodies that bind residue K169 in the V2 region of the HIV-1 envelope correlated with reduced risk of infection in the RV144 vaccine trial but were restricted to two ED-motif-encoding light chain genes. Here, we identify an HIV-infected donor with high-titer V2 peptide-binding antibodies and isolate two antibody lineages (CAP228-16H/19F and CAP228-3D) that mediate potent antibody-dependent cell-mediated cytotoxicity (ADCC). Both lineages use the IGHV5-51 heavy chain germline gene, similar to the RV144 antibody CH58, but one lineage (CAP228-16H/19F) uses a light chain without the ED motif. A cocrystal structure of CAP228-16H bound to a V2 peptide identified a IGLV3-21 gene-encoded DDxD motif that is used to bind K169, with a mechanism that allows CAP228-16H to recognize more globally relevant V2 immunotypes. Overall, these data further our understanding of the development of cross-reactive, V2-binding, antiviral antibodies and effectively expand the human light chain repertoire able to respond to RV144-like immunogens.

Legend

Protein

Chemical

Disease

Primary Citation of related structures